查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790180

美国Dupixent 市场规模、份额和趋势分析报告：按适应症、分销管道、地区和细分市场预测，2025 年至 2033 年

U.S. Dupixent Market Size, Share & Trends Analysis Report By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国Dupixent 市场摘要

预计 2024 年美国Dupixent 市场规模为 103.9 亿美元，预计 2033 年将达到 168.2 亿美元，2025 年至 2033 年的复合年增长率为 5.47%。由于医疗保健覆盖面广，美国主导市场成长。

美国Dupixent 产业的发展受到异位性皮肤炎、气喘和伴随鼻息肉的慢性鼻窦炎 (CRSwNP) 等慢性发炎性疾病盛行率上升的推动。 FDA 于 2024 年 9 月核准Dupixent 用于治疗慢性阻塞性肺病(COPD)，尤其是青少年患者，这扩大了该药物的治疗范围。

Dupixent 是一种针对白细胞介素4 (IL-4) 和白细胞介素13 (IL-13) 路径的单株抗体，旨在满足中度至重度发炎性疾病中尚未满足的临床需求。它是美国市场领先的生物製药，在治疗异位性皮肤炎和重度气喘方面已被证实有效。

医疗保健基础设施和支出趋势正在推动这种药物的普及。预计到2023年，美国的医疗保健支出将达到4.9兆美元，这得益于生物製药的广泛使用和专科护理需求的不断增长。然而，由于有2,600万名用户没有医疗保险，报销差距仍是市场准入的限制因素。儘管有这些限制，但20%的患者使用的远端医疗正在改善都市区的医疗可近性。相较之下，占人口19%的农村地区仍面临医疗可近性的限制。

美国65岁以上人口已达5,800万，人口老化加剧了慢性阻塞性肺病（COPD）的发生率，进一步拉动了市场需求。此外，由于环境因素，异位性皮肤炎和气喘病例每年以2%的速度成长，这也推动了市场的成长。

Dupixent 可皮下给药，其安全性优于皮质类固醇，从而提高了患者的依从性。赛诺菲和市场支持的真实世界证据研究得到了新的研发管线创新（包括嗜伊红性食道炎的创新）、优化的给药方案和扩大的生产能力的支持。然而，高昂的治疗费用和服务欠缺地区的有限覆盖仍然是一项挑战。我们正在实施策略合作伙伴关係和患者支援计划以解决这些障碍，这将有助于公司在 2033 年之前保持持续的成长势头。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国Dupixent 市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章：美国Dupixent 市场（按适应症、估计和趋势分析）

  • 2024 年及 2033 年各适应症市场占有率
  • 细分仪表板：依指示
  • 2021 年至 2033 年市场规模、预测与趋势分析（按适应症）
  • 异位性皮肤炎（AD）
  • 气喘
  • 慢性鼻窦炎伴随鼻息肉（CRSwNP）
  • 慢性阻塞性肺病（COPD）
  • 其他的

第五章：美国Dupixent 市场通路预测及趋势分析

  • 2024 年和 2033 年按分销管道分類的市场占有率
  • 细分仪表板：按分销管道
  • 2021 年至 2033 年按分销管道分類的市场规模、预测和趋势分析
  • 医院药房
  • 零售药局
  • 其他的

第六章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Sanofi
    • Regeneron
Product Code: GVR-4-68040-660-4

U.S. Dupixent Market Summary

The U.S. dupixent market size was estimated at USD 10.39 billion in 2024 and is projected to reach USD 16.82 billion by 2033, growing at a CAGR of 5.47% from 2025 to 2033. The market growth dominates due to high healthcare access in the U.S.

The U.S. dupixent industry is driven by the rising prevalence of chronic inflammatory conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). The recent FDA approval for chronic obstructive pulmonary disease (COPD) in September 2024, particularly in adolescent patients, has expanded the drug's therapeutic scope.

Dupixent, a monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, addresses unmet clinical needs in moderate-to-severe inflammatory diseases. Its demonstrated efficacy in atopic dermatitis and severe asthma has positioned it as a leading biologic in the U.S. market.

Healthcare infrastructure and expenditure trends support the drug's adoption. The U.S. recorded USD 4.9 trillion in healthcare spending in 2023, driven by increasing biologic uptake and demand for specialty care. However, 26 million uninsured Americans and reimbursement gaps remain a constraint on market reach. Despite these limitations, telehealth adoption, utilized by 20% of patients, has improved access in urban settings. In contrast, rural areas, which account for 19% of the population, continue to face access limitations.

The aging population, with 58 million Americans over the age of 65, is contributing to rising COPD prevalence, further supporting demand. In addition, the annual 2% rise in atopic dermatitis and asthma cases, largely due to environmental factors, reinforces market growth.

Dupixent's subcutaneous administration and favorable safety profile compared to corticosteroids improve patient compliance. Real-world evidence studies, backed by Sanofi and the market, are supported by emerging pipeline innovations such as eosinophilic esophagitis, optimized dosing regimens, and expanded manufacturing capacity. However, high treatment costs and coverage limitations in underserved regions pose challenges. Strategic collaborations and patient assistance programs are being implemented to address these barriers, sustaining growth momentum through 2033.

U.S. Dupixent Market Report Segmentation

This report forecasts revenue growth for the U.S. and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. dupixent market report based on indication and distribution channel:

  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Atopic Dermatitis (AD)
  • Asthma
  • Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Dupixent Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Dupixent Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
  • 4.4. Atopic Dermatitis (AD)
    • 4.4.1. Atopic Dermatitis (AD) Market, 2021 - 2033 (USD Billion)
  • 4.5. Asthma
    • 4.5.1. Asthma Market, 2021 - 2033 (USD Billion)
  • 4.6. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    • 4.6.1. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, 2021 - 2033 (USD Billion)
  • 4.7. Chronic Obstructive Pulmonary Disease (COPD)
    • 4.7.1. Chronic Obstructive Pulmonary Disease (COPD) Market, 2021 - 2033 (USD Billion)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. U.S. Dupixent Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Competitive Landscape

  • 6.1. Participant Overview
  • 6.2. Company Market Position Analysis
  • 6.3. Company Categorization
  • 6.4. Strategy Mapping
  • 6.5. Company Profiles/Listing
    • 6.5.1. Sanofi
      • 6.5.1.1. Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Product Benchmarking
      • 6.5.1.4. Strategic Initiatives
    • 6.5.2. Regeneron
      • 6.5.2.1. Overview
      • 6.5.2.2. Financial Performance
      • 6.5.2.3. Product Benchmarking
      • 6.5.2.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. Dupixent market, by region, 2021 - 2033 (USD Billion)
  • Table 4 U.S. Dupixent market, by indication, 2021 - 2033 (USD Billion)
  • Table 5 U.S. Dupixent market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 U.S. Dupixent market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Billion)
  • Fig. 10 Competitive landscape
  • Fig. 11 Dupixent market dynamics
  • Fig. 12 Dupixent market: Porter's five forces analysis
  • Fig. 13 Dupixent market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Billion)
  • Fig. 15 Atopic Dermatitis (AD) market, 2021 - 2033 (USD Billion)
  • Fig. 16 Asthma market, 2021 - 2033 (USD Billion)
  • Fig. 17 Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) market, 2021 - 2033 (USD Billion)
  • Fig. 18 Chronic Obstructive Pulmonary Disease (COPD) market, 2021 - 2033 (USD Billion)
  • Fig. 19 Others market, 2021 - 2033 (USD Billion)
  • Fig. 20 Distribution Channel market, 2021 - 2033 (USD Billion)
  • Fig. 21 Hospital Pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 22 Retail Pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 23 Others market, 2021 - 2033 (USD Billion)
  • Fig. 24 Company categorization
  • Fig. 25 Company market position analysis
  • Fig. 26 Strategic framework